Ibutamoren (MK-677) Oral vs Tesamorelin
A side-by-side research comparison of Ibutamoren (MK-677) Oral and Tesamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Ibutamoren (MK-677) Oral | Tesamorelin |
|---|---|---|
| Full name | Ibutamoren Mesylate (MK-677) | Tesamorelin Acetate (Egrifta) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | FDA Approved |
| Mechanism | Mimics ghrelin at the GHS-R1a receptor in the pituitary and hypothalamus, stimulating sustained GH release without suppressing natural pulsatility. Also increases appetite via ghrelin pathway activation. | Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis. |
| Molecular weight | 528.66 Da | 5,136 Da |
| Half-life | ~24 hours | 26-38 minutes |
| Bioavailability | ~60% oral | High (SubQ) |
| Typical dose | 10-25 mg | 2 mg |
| Frequency | Once daily (evening) | Once daily |
| Route | Oral capsule or liquid | Subcutaneous injection |
Ibutamoren (MK-677) Oral reported benefits
- Elevated IGF-1 levels
- Improved sleep quality
- Enhanced recovery
- Increased lean mass
- Better skin/hair
- Convenient oral dosing
Tesamorelin reported benefits
- Visceral fat reduction (up to 18%)
- FDA-approved safety
- Improved lipid panels
- Cognitive benefits (emerging)
- No significant IGF-1 overshoot
Related comparisons
Research and educational reference only. Not medical advice.